Loading...
Speciality Medicines Limited — Pembrolizumab Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #7 for Pembrolizumab · $159.1K export value · DGFT Verified
Speciality Medicines Limited is the #7 Indian exporter of Pembrolizumab with $159.1K in export value and 20 verified shipments. Speciality Medicines Limited holds a 8.2% market share in Pembrolizumab exports across 2 countries. The company exports 6 pharmaceutical products worth $345.1K across 2 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| BRAZIL | $285.4K | 34 | 89.5% |
| ST KITTS-NEVIS-ANGUILLA | $19.7K | 2 | 6.2% |
| LITHUANIA | $13.7K | 3 | 4.3% |
Speciality Medicines Limited exports Pembrolizumab to 3 countries. The largest destination is BRAZIL accounting for 89.5% of Speciality Medicines Limited's Pembrolizumab shipments, followed by ST KITTS-NEVIS-ANGUILLA (6.2%) and LITHUANIA (4.3%). These destinations reflect Speciality Medicines Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | BRAZIL | $222.0K | 27 |
| TO THE ORDER OF | BRAZIL | $55.4K | 7 |
| TO THE ORDER OF. | BRAZIL | $12.9K | 2 |
| BETANIA DALBEM DIAS PETIERA | BRAZIL | $9.5K | 1 |
| PATIENT BETANIA DALBEM DIAS | BRAZIL | $9.5K | 1 |
| PATIENT: BETANIA DALBEM DIAS PEREIR | BRAZIL | $9.5K | 1 |
India exported $1.7M worth of Pembrolizumab through 215 shipments from 34 suppliers to 21 countries, serving 66 buyers globally. Speciality Medicines Limited contributes $159.1K to this total, accounting for 8.2% of India's Pembrolizumab exports. Speciality Medicines Limited ships Pembrolizumab to 3 countries through 6 buyers.
Speciality Medicines Limited's average Pembrolizumab shipment value is $8.0K per consignment, based on 20 shipments totaling $159.1K. The largest destination is BRAZIL (89.5% of Speciality Medicines Limited's Pembrolizumab exports).
Speciality Medicines Limited ranks #7 among 34 Indian Pembrolizumab exporters with a 8.2% market share. The top 3 exporters are GNH INDIA PHARMACEUTICALS LIMITED ($285.3K), GEMINI HEALTHWORLD LLP ($212.6K), 3S PHARMACEUTICALS INDIA PRIVATE LIMITED ($201.7K). Speciality Medicines Limited processed 20 shipments to 2 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB 100MG/4ML INJECTION | $149.2K | 19 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB INJECTION 100 MG /4ML | $32.2K | 4 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB INJECTION 100MG/4ML | $20.0K | 2 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB 100MG/4ML INJECTIONSET | $19.1K | 2 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE:PEMBROLIZUMAB INJECTION 100MG/4ML | $18.3K | 2 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB 100MG/4ML INJECTIONNOS | $12.9K | 2 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB 100MG/4ML INJECTION AS PER INVOICE | $11.3K | 1 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE- PEMBROLIZUMAB 100MG/4ML INJECTION,BATCH NO: X018554SET |
What Speciality Medicines Limited must comply with to export Pembrolizumab to its top destination countries
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | SHREE KRISHNA LIFECARE | $174.0K | 10 | 3 | $17.4K |
| 6 | SPECIALITY MEDICINES PRIVATE LIMITED | $159.8K | 19 | 3 | $8.4K |
| 7 | SPECIALITY MEDICINES LIMITED ★ | $159.1K | 20 | 2 | $8.0K |
| 8 | NU HOSPITALS PRIVATE LIMITED | $130.1K | 30 | 1 |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 47 | 21.9% |
| AHEMDABAD AIR ACC (INAMD4) | 33 | 15.3% |
| DELHI AIR CARGO ACC (INDEL4) | 25 | 11.6% |
| DELHI AIR | 19 | 8.8% |
| AHEMDABAD AIR | 17 | 7.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 15 | 7.0% |
| BANGALORE ACC (INBLR4) | 13 | 6.0% |
| BANGALORE AIR | 10 | 4.7% |
Speciality Medicines Limited also exports these advanced oncology products. Each links to the detailed product page.
Speciality Medicines Limited exports 6 products worth $345.1K. Beyond Pembrolizumab, top products include Olaparib, Ustekinumab, Lenvatinib, Nivolumab, Cabozantinib. View the complete Speciality Medicines Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Pembrolizumab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Speciality Medicines Limited's Pembrolizumab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Speciality Medicines Limited
Full Company Profile →
6 products · $345.1K total trade · 2 categories
Speciality Medicines Limited supplies Pembrolizumab to 6 buyers globally. The largest buyer is TO THE ORDER (BRAZIL), followed by TO THE ORDER OF (BRAZIL) and TO THE ORDER OF. (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $9.5K |
| 1 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB 100 MG/4ML INJECTION AS PER INVOICESET | $9.2K | 1 |
| HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMAB INJECTION 100 MG 4ML | $9.1K | 1 |
Speciality Medicines Limited exports 14 distinct Pembrolizumab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HARMLESS PHARMACEUTICAL MEDICINES FOR HUMAN USE PEMBROLIZUMA with 19 shipments worth $149.2K.
| $4.3K |
| 9 | G P INTERGLOBE | $59.9K | 6 | 1 | $10.0K |
Speciality Medicines Limited ranks #7 among 34 Indian Pembrolizumab exporters. Average shipment value of $8.0K compared to the market average of $50.2K. The closest competitors by value are SHREE KRISHNA LIFECARE and SPECIALITY MEDICINES PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 21+ countries, 66+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Speciality Medicines Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Pembrolizumab. For current shipment-level data, contact TransData Nexus.